nonacog beta pegol
Biologicalexperimental
Factor IX, also known as Christmas factor, is one of the serine proteases involved in coagulation; it belongs to peptidase family S1. Deficiency of this protein causes haemophilia B. — Wikipedia
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
6
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT00956345)
Timeline
Indications
Studied for
Mechanism of action
- Coagulation factor IXEXOGENOUS PROTEIN
Coagulation factor IX exogenous protein
- Coagulation factor VIIISupplementation
F8 supplementation
- Coagulation factor IXSupplementation
F9 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFactor IX ↗
- NCATS27Y83O992Q ↗
- ChEMBLCHEMBL2108348 ↗
Also known as
- n9-gp
- n9-gp compound
- nonacog beta
- nonacog beta pegol
- nonacog beta pegol
- nonacog beta pegol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05365217 | Phase 3 | May 18, 2022 | Novo Nordisk |
| NCT03075670 | Phase 1 | Mar 7, 2017 | Novo Nordisk |
| NCT02141074 | Phase 3 | Jul 2, 2014 | Novo Nordisk |
| NCT01386528 | Phase 3 | Jun 7, 2012 | Novo Nordisk |
| NCT01467427 | Phase 3 | May 16, 2012 | Novo Nordisk |
| NCT01395810 | Phase 3 | Apr 16, 2012 | Novo Nordisk |
| NCT01333111 | Phase 3 | Apr 1, 2011 | Novo Nordisk |
| NCT00956345 | Phase 1 | Aug 1, 2009 | Novo Nordisk |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 8 | 8 | 2 | 2009 |
1 organizations
Page 1 / 1